
    
      Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will
      be proposed to participate to the present study. After signing the patient informed consent,
      both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval.

      No adverse events are expected.
    
  